… mellitus, sitagliptin 100 mg was the most effective dose across various glycaemic parameters
[15, 16]. The current study assessed the safety and efficacy of once-daily sitagliptin 100 mg …

… To avoid the confounding influence of rescue therapy on efficacy comparisons, in efficacy …
The primary efficacy hypothesis for this study was that the addition of sitagliptin 100 mg …

… , the addition of sitagliptin compared with glipizide provided similar HbA 1c ‐lowering
efficacy over 52 weeks in patients on ongoing metformin therapy. Sitagliptin was generally well …

… In this study, the efficacy and tolerability profile of adding sitagliptin 100 mg or placebo to …
the overall study population, the efficacy and tolerability of sitagliptin relative to placebo in the …

… Objective The efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin added
… Patients were randomized in a 1:1 ratio to receive sitagliptin 100 nag once daily or placebo …

… Therefore, in the present SUCCESS-2 (Study for an Ultimate Combination therapy to
Control diabetES with Sitagliptin) trial, we aimed to assess the efficacy and safety of sitagliptin …

… -1 (SUCCESS-1) trial, focusing on the choice of the second-line drug, we aimed to assess
the efficacy and safety of sitagliptin compared with an α-glucosidase inhibitor in Japanese …

… This study was designed to assess the efficacy and safety of a dipeptidyl peptidase-4
inhibitor, gemigliptin versus sitagliptin added to metformin in patients with type 2 diabetes. …

… a dipeptidyl peptidase‐4 (DPP‐4) inhibitor and/or a sulphonylurea. Those on metformin +
sitagliptin … to metformin + sitagliptin (discontinuing other DPP‐4 inhibitors and sulphonylureas) …

… of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or
the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately …